Rigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML
Durable remissions observed in patients relapsed or refractory to prior venetoclax-based regimens Data featured in a poster presentation at the European Hematology Association (EHA) 2023 Hybrid Congress SOUTH SAN FRANCISCO, Calif., June 7, 2023 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced promising data from an analysis of the Phase 2 study evaluating REZLIDHIA® … Read more